AU4417000A - Novel pharmaceutical composition suitable for gene therapy - Google Patents

Novel pharmaceutical composition suitable for gene therapy

Info

Publication number
AU4417000A
AU4417000A AU44170/00A AU4417000A AU4417000A AU 4417000 A AU4417000 A AU 4417000A AU 44170/00 A AU44170/00 A AU 44170/00A AU 4417000 A AU4417000 A AU 4417000A AU 4417000 A AU4417000 A AU 4417000A
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
gene therapy
composition suitable
novel pharmaceutical
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44170/00A
Inventor
Richard Charles Boucher
Martin James Ford
Larry Goldoc Johnson
Yim Man
Michael Robert West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Original Assignee
Glaxo Group Ltd
University of North Carolina at Chapel Hill
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9908636.5A external-priority patent/GB9908636D0/en
Priority claimed from GBGB9908643.1A external-priority patent/GB9908643D0/en
Priority claimed from GBGB9909073.0A external-priority patent/GB9909073D0/en
Priority claimed from GBGB9909297.5A external-priority patent/GB9909297D0/en
Application filed by Glaxo Group Ltd, University of North Carolina at Chapel Hill, University of North Carolina System filed Critical Glaxo Group Ltd
Publication of AU4417000A publication Critical patent/AU4417000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
AU44170/00A 1999-04-15 2000-04-13 Novel pharmaceutical composition suitable for gene therapy Abandoned AU4417000A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB9908643 1999-04-15
GB9908636 1999-04-15
GBGB9908636.5A GB9908636D0 (en) 1999-04-15 1999-04-15 Novel pharmaceutical composition
GBGB9908643.1A GB9908643D0 (en) 1999-04-15 1999-04-15 Novel pharmaceutical composition
GB9909073 1999-04-20
GBGB9909073.0A GB9909073D0 (en) 1999-04-20 1999-04-20 Novel pharmaceutical composition
GB9909297 1999-04-22
GBGB9909297.5A GB9909297D0 (en) 1999-04-22 1999-04-22 Novel pharmaceutical composition
US15375799P 1999-09-13 1999-09-13
US60153757 1999-09-13
PCT/GB2000/001408 WO2000062815A2 (en) 1999-04-15 2000-04-13 Novel pharmaceutical composition suitable for gene therapy

Publications (1)

Publication Number Publication Date
AU4417000A true AU4417000A (en) 2000-11-02

Family

ID=27517502

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44170/00A Abandoned AU4417000A (en) 1999-04-15 2000-04-13 Novel pharmaceutical composition suitable for gene therapy

Country Status (2)

Country Link
AU (1) AU4417000A (en)
WO (1) WO2000062815A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410419A1 (en) * 2000-05-30 2001-12-06 Ich Productions Limited Improved methods of transfection
GB0106315D0 (en) * 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
US7105347B2 (en) * 2002-07-30 2006-09-12 Corning Incorporated Method and device for protein delivery into cells
US7691580B2 (en) 2003-01-29 2010-04-06 Corning Incorporated Reverse protein delivery into cells on coded microparticles
ES2491166T3 (en) * 2003-11-15 2014-09-05 Polyphor Ltd. Beta fork loop mimetics fixed to pattern and their use in phage exposure
WO2015143254A1 (en) * 2014-03-21 2015-09-24 The Regents Of The University Of Michigan Pharmaceutical compositions comprising occludin mutants and methods of inhibiting angiogenesis therewith
CN116621966A (en) * 2022-05-06 2023-08-22 珠海丽凡达生物技术有限公司 Therapeutic nucleic acid molecules, mixtures, medicaments and their use in the treatment of solid tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05500504A (en) * 1989-09-27 1993-02-04 アテナ・ニュウロサイエンスィズ・インコーポレイテッド Composition and method of use for inhibiting cell adhesion
US6252045B1 (en) * 1996-03-15 2001-06-26 Yale University Human occludin, its uses and enhancement of drug absorption using occludin inhibitors
CA2259966A1 (en) * 1996-07-12 1998-01-22 Mcgill University Compounds and methods for modulating cell adhesion
DE69835601D1 (en) * 1997-09-24 2006-09-28 Merrion Res I Ltd COMPOSITIONS AND METHODS FOR INCREASING PARAZELLULAR TRANSPORT BY CELL LAYERS
CA2271826A1 (en) * 1998-11-16 2000-05-16 Douglas J. Jolly Methods and compositions for increasing the infectively of retroviruses

Also Published As

Publication number Publication date
WO2000062815A2 (en) 2000-10-26
WO2000062815A3 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
AU1071301A (en) Pharmaceutical compounds
AU6011496A (en) Improved pharmaceutical compositions for gene therapy
AU7912100A (en) Pharmaceutical composition comprising an antigen
AU5259100A (en) Medicament
AU3192700A (en) Medicinal compositions
AU2270101A (en) Pharmaceutical kit
AU5326100A (en) Pharmaceutical compositions and methods for use
AU3556400A (en) Pharmaceutical compositions
AU1887401A (en) Medicinal composition
AU2005300A (en) Medicinal compositions
AU4328800A (en) Pharmaceutical formulation
AU1735001A (en) Cyclodextrin-containing pharmaceutical composition
AU6715600A (en) Pharmaceutical formulations
AU4304400A (en) Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives
AU5460800A (en) Pharmaceutical transdermal compositions
AU6460400A (en) Pharmaceutical compositions
AU4417000A (en) Novel pharmaceutical composition suitable for gene therapy
AU7937500A (en) Pharmaceutical composition containing midazolam
AU4977300A (en) Pharmaceutical formulations
AU1385801A (en) Pharmaceutical formulations
AU5722900A (en) Pharmaceutical compounds
AU6460200A (en) Pharmaceutical compositions
AU2001292301A1 (en) Novel drugs for liver diseases
AU5836700A (en) Peptides for therapeutic use
AU6460300A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase